Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Freemantle

Showing results (21-30 of 420) with videos related to

Pageof 42
Sort By:
BMJ (Clinical Research Ed.)|March 22, 2008
Observational evidence for determining drug safetyNick Freemantle, Alar Irs
Diabetes, Obesity & Metabolism|March 23, 2019
Comment on "a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes"Nick Freemantle, Sophie Jourdan
Pharmacoeconomics|July 16, 2003
A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?Suzanne Hill, Nick Freemantle
Applied Health Economics and Health Policy|February 5, 2020
Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'Livio Garattini, Nick Freemantle
Lancet (London, England)|February 28, 2021
Concerns with the new SYNTAX scoreNick Freemantle, Domenico Pagano
Family Practice|July 14, 2004
The commercialization of clinical research: who pays the piper, calls the tune?Nick Freemantle, Deborah Stocken
BMJ (Clinical Research Ed.)|September 23, 2015
Catalogue of errors in papers reporting clinical trialsNick Freemantle, Greta Rait
BMJ (Clinical Research Ed.)|April 14, 2007
Composite and surrogate outcomes in randomised controlled trialsNick Freemantle, Mel Calvert
BMJ (Clinical Research Ed.)|December 10, 2009
What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?Nick Freemantle, Mel Calvert
BMJ (Clinical Research Ed.)|August 20, 2010
Interpreting composite outcomes in trialsNick Freemantle, Melanie J Calvert
Pageof 42

Showing results (21-30 of 420) with videos related to

Sort By:
Pageof 42
BMJ (Clinical Research Ed.)|March 22, 2008
Observational evidence for determining drug safetyNick Freemantle, Alar Irs
Diabetes, Obesity & Metabolism|March 23, 2019
Comment on "a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes"Nick Freemantle, Sophie Jourdan
Pharmacoeconomics|July 16, 2003
A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?Suzanne Hill, Nick Freemantle
Applied Health Economics and Health Policy|February 5, 2020
Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'Livio Garattini, Nick Freemantle
Lancet (London, England)|February 28, 2021
Concerns with the new SYNTAX scoreNick Freemantle, Domenico Pagano
Family Practice|July 14, 2004
The commercialization of clinical research: who pays the piper, calls the tune?Nick Freemantle, Deborah Stocken
BMJ (Clinical Research Ed.)|September 23, 2015
Catalogue of errors in papers reporting clinical trialsNick Freemantle, Greta Rait
BMJ (Clinical Research Ed.)|April 14, 2007
Composite and surrogate outcomes in randomised controlled trialsNick Freemantle, Mel Calvert
BMJ (Clinical Research Ed.)|December 10, 2009
What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?Nick Freemantle, Mel Calvert
BMJ (Clinical Research Ed.)|August 20, 2010
Interpreting composite outcomes in trialsNick Freemantle, Melanie J Calvert
Pageof 42